Exhibit 99.1

TearLab Corporation Reports Fourth Quarter and Full Year 2019 Financial Results

ESCONDIDO, Calif., March 5, 2020 — TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the fourth quarter and twelve months ended December 31, 2019. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.

Recent Highlights

- Fourth quarter revenue of $5.5 million

- Cash position of $7.1 million as of December 31, 2019

- Expanded the U.S. active device base to 4,834 and active accounts to 1,854 TearLab Osmolarity Systems

For the three months ended December 31, 2019, TearLab’s net revenues were $5.5 million, down 8.3% from $6.0 million for the same period in 2018.

The following table sets out the estimated annualized revenue per U.S. device and account analysis for the fourth quarter ended December 31, 2019:

					Annualized		Annualized
	Active		Active		Revenue		Revenue
Program	Devices		Accounts		Per Device		Per Account
Purchased		1,308		1,083	$	2,164	$	2,613
Masters		1,767		209	$	2,868	$	24,245
Flex		1,759		562	$	6,618	$	20,713
Total		4,834		1,854

The Company’s reported net loss for the 2019 fourth quarter was approximately $1.2 million, or ($0.09) basic loss per share, compared to a reported net loss of approximately $0.5 million, or ($0.05) basic loss per share in the fourth quarter of 2018.

“We were pleased to continue the expansion of our customer base throughout 2019,” said Seph Jensen, TearLab’s Chief Executive Officer. “We remain focused on the resubmission of our 510(k) application to secure FDA clearance of our next-generation TearLab Discovery™ System.”

About TearLab Corporation

TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. TearLab Corporation’s common shares trade on the OTCQB Market under the symbol ‘TEAR’.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, the ability to capitalize on the current market momentum for osmolarity and to bring the Tearlab Discovery™ system to the U.S. market. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management’s current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019. We do not undertake to update any forward-looking statements except as required by law.

CONTACT: Investor Contact:

The Ruth Group

James Salierno / Cameron Willis

Tel: 646-536-7028 / 7038

jsalierno@theruthgroup.com / cwillis@theruthgroup.com

TearLab Corp.

Consolidated Statements of Operations

(Expressed in U.S. Dollars (000’s) except for number of shares and net loss per share)

(Unaudited)

	Three months
	December 31,
	2019			2018
Revenue
Product sales	$	4,810		$	5,275
Reader equipment rentals		683			713
Total revenue		5,493			5,988
Cost of goods sold
Cost of goods sold (excluding amortization of intangible assets)		1,945			2,143
Cost of goods sold - reader equipment depreciation		78			186
Gross profit		3,470			3,659
Operating expenses
Sales and marketing		889			596
Clinical, regulatory and research & development		894			822
General and administrative		1,349			1,492
Total operating expenses		3,132			2,910
Income from operations		338			749
Other income (expense)		(1,490	)		(1,261	)
Net loss and comprehensive loss	$	(1,152	)	$	(512	)
Weighted average shares outstanding – basic and diluted		12,560,635			11,296,998
Net loss per share – basic and diluted	$	(0.09	)	$	(0.05	)

TearLab Corp.

Consolidated Statements of Operations

(Expressed in U.S. Dollars (000’s) except for number of shares and net loss per share)

	Years ended December 31,
	2019			2018
Revenue
Product sales	$	19,903		$	22,153
Reader equipment rentals		2,752			2,846
Total revenue		22,655			24,999
Cost of goods sold
Cost of goods sold (excluding amortization of intangible assets)		7,909			8,495
Cost of goods sold - reader equipment depreciation		447			961
Gross profit		14,299			15,543
Operating expenses
Sales and marketing		3,652			3,334
Clinical, regulatory and research & development		3,817			3,587
General and administrative		6,555			6,160
Total operating expenses		14,024			13,081
Income from operations		275			2,462
Other income (expense)		(5,691	)		(4,713	)
Net loss and comprehensive loss	$	(5,416	)	$	(2,251	)
Weighted average shares outstanding - basic and diluted		12,178,565			10,615,513
Net loss per share – basic and diluted	$	(0.44	)	$	(0.21	)

TearLab Corp.

Condensed Consolidated Balance Sheet

(Expressed in U.S. Dollars (000’s) except for number of shares and net loss per share)

	December 31,			December 31,
	2019			2018
ASSETS
Current assets
Cash	$	7,108		$	8,473
Accounts receivable, net		917			1,186
Inventory		2,269			1,987
Prepaid expenses and other current assets		1,562			690
Total current assets		11,856			12,336
Fixed assets, net		1,670			2,024
Intangible assets, net		2			2
Right of use assets		645			-
Other non-current assets		120			151
Total assets	$	14,293		$	14,513
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities
Accounts payable	$	599		$	681
Accrued liabilities		2,336			2,363
Deferred Rent		2			13
Current portion of long-term debt		36,578			-
Current portion of lease liability		240			-
Total current liabilities		39,755			3,057
Long-term debt, net		-			32,014
Long-term lease liability, net of current portion		429			-
Long-term third party payable		130			111
Total liabilities		40,314			35,182
Stockholders’ deficit
Capital stock
Preferred Stock, $0.001 par value, 10,000,000 authorized, 0 and 556 issued and outstanding at December 31, 2019 and December 31, 2018, respectively		-			-
Common stock, $0.001 par value, and 40,000,000 authorized, 12,560,635 and 11,296,998 issued and outstanding at December 31, 2019 and December 31, 2018, respectively		13			11
Additional paid-in capital		510,442			510,380
Accumulated deficit		(536,476	)		(531,060	)
Total stockholders’ deficit		(26,021	)		(20,669	)
Total liabilities and stockholders’ deficit	$	14,293		$	14,513